United States Ovarian Cancer Diagnostics Market to Grow with a CAGR of 5.79% through 2029
Growing incidence and
prevalence of ovarian cancer is expected to drive the United States Ovarian
Cancer Diagnostics Market in the forecast period 2025-2029
According to TechSci Research report, “United States Ovarian Cancer Diagnostics Market, By Region and Competition, Opportunity, and Forecast, 2019-2029F”, the United
States Ovarian Cancer Diagnostics Market stood at USD 284.13 million in 2023
and is anticipated to grow with a CAGR of 5.79% in the forecast period, 2025-2029.
Ovarian cancer is a challenging adversary in the world of oncology. Known as
the "silent killer" due to its often-asymptomatic early stages, it is
crucial to diagnose and treat ovarian cancer as early as possible. The
rising incidence of ovarian cancer in the United States is a significant driver
for the diagnostics market. According to the American Cancer Society, ovarian
cancer ranks fifth in cancer-related deaths among women. As the population ages
and risk factors like obesity become more prevalent, the demand for ovarian
cancer diagnostics continues to surge. Early diagnosis is the cornerstone of
successful treatment, prompting both patients and healthcare providers to
prioritize screening and diagnostic tests.
The rapid evolution of diagnostic
technologies is another major driver in the United States Ovarian Cancer
Diagnostics Market. Traditional methods like ultrasound and blood tests
(CA-125) are being complemented and, in some cases, replaced by more advanced
approaches. Innovations such as liquid biopsies, which detect cancer-related
DNA or proteins in the bloodstream, offer non-invasive and highly sensitive
early detection capabilities. The molecular diagnostics and genetic
testing have paved the way for personalized treatment plans, tailoring
therapies to an individual's genetic makeup. Ovarian cancer presents a
formidable challenge in oncology, spurring demand for early detection solutions
in the United States. Its asymptomatic early stages drive urgency, given its
high mortality rate among women. The evolving landscape of diagnostic technologies
is reshaping the market, with advanced methods like liquid biopsies and genetic
testing enhancing detection sensitivity and personalized treatment strategies.
Heightened awareness campaigns, particularly during Ovarian Cancer Awareness
Month in September, bolster screening efforts, especially for high-risk
individuals. Collaboration among academia, research institutions, and
pharmaceutical firms fuels innovation, advancing diagnostic accuracy and
treatment efficacy through clinical trials. As the population ages and risk
factors like obesity rise, the need for effective ovarian cancer diagnostics
intensifies, underscoring the importance of ongoing advancements and awareness
initiatives.
Browse over XX market data
Figures spread through XX Pages and an in-depth TOC on "United
States Ovarian Cancer Diagnostics Market.”
The United States Ovarian Cancer Diagnostics
Market is segmented into diagnosis type, cancer type, end
use, regional distribution, and company.
Based on cancer type, Epithelial tumors
emerged as the dominant segment in the United States market for United States
Ovarian Cancer Diagnostics Market in 2023. Epithelial tumors are the
dominant subtype among ovarian cancers. These tumors originate from the cells
lining the surface of the ovaries and are the most common type, accounting for
approximately 90% of cases. Their dominance is attributed to their diverse
histological subtypes and aggressive nature, often leading to late-stage
diagnosis. The epithelial tumors are associated with various risk
factors such as age, genetic mutations, and hormonal factors. Their prevalence
underscores the importance of effective screening and diagnostic measures to
improve early detection and treatment outcomes in ovarian cancer management.
Based on the End Use, Cancer Diagnostic
Centers emerged as the dominant segment in the United States Ovarian Cancer
Diagnostics Market in 2023 due to their specialized expertise and comprehensive
diagnostic capabilities. These centers house multidisciplinary teams of
oncologists, radiologists, pathologists, and other specialists dedicated to
cancer diagnosis. Their focused approach enables timely and accurate
evaluations of patients with potential ovarian cancer symptoms or risk factors.
With early diagnosis being critical for improved outcomes, patients and
healthcare providers increasingly rely on Cancer Diagnostic Centers for
advanced screening, genetic testing, imaging, and biopsy services, driving
their prominence in the market.
Based on region, Mid-West emerged as the
dominant player in the United States Ovarian Cancer Diagnostics Market in 2023,
holding the largest market share. The Mid-West emerged as the dominant player
in the United States Ovarian Cancer Diagnostics Market in 2023 due to several
factors. Firstly, the region's extensive network of healthcare facilities,
including cancer diagnostic centers and research institutions, provided robust
infrastructure for early detection and diagnosis. The Mid-West's
proactive approach to healthcare, coupled with high levels of awareness about
ovarian cancer and screening initiatives, led to increased demand for diagnostic
services. The region's emphasis on precision medicine and
collaborative research efforts further strengthened its position in offering
advanced diagnostic technologies and personalized treatment options, driving
its dominance in the market.
Major companies operating
in United States Ovarian Cancer Diagnostics Market are:
- Abbott Laboratories Inc.
- F. Hoffmann-La Roche
Ltd.
- GlaxoSmithKline plc
- Johnson & Johnson
- AstraZeneca plc
- Siemens Healthcare GmbH
- Quest Diagnostics
Incorporated
- Thermo Fisher Scientific
Inc
- Bio-Rad Technologies Inc
- Eli Lily and Company
Download Free Sample Report
Customers can also request
for 10% free customization on this report.
“The United States Ovarian Cancer Diagnostics
(NGS) market is poised for significant growth in the coming years. Rising
ongoing advancements in diagnostic technologies, the increasing awareness of
ovarian cancer and the importance of early detection is bolstering the market
growth within United States. With the rise of molecular diagnostics, liquid
biopsies, and artificial ntelligence, the field is becoming increasingly
precise and accessible. Government support, research funding, and patient
advocacy are further driving progress. The integration of telehealth
services and the evolving healthcare landscape are expected to enhance
accessibility to diagnostic services” said Mr. Karan Chechi, Research Director
with TechSci Research, a research-based management consulting firm.
“United States Ovarian Cancer
Diagnostics Market Segmented By Diagnosis Type (Imaging, Blood Test, Biopsy,
Others), By Cancer Type (Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor,
Others), By End Use (Hospital Laboratories, Cancer Diagnostic Centers, Research
Institutes, Others) Region and Competition, Opportunity, and Forecast, 2019-2029F”, has evaluated the future growth potential
of United States Ovarian Cancer Diagnostics Market and provides statistics
& information on market size, structure and future market growth. The
report intends to provide cutting-edge market intelligence and help decision
makers take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in United States Ovarian Cancer Diagnostics Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel:
+13322586602
Email: [email protected]
Website: www.techsciresearch.com